OnKure Therapeutics
Develops mutation-selective PI3Kα medicines for cancer and vascular anomalies.
$3.79
After-hours close0.00 (0.00%)
At close$3.79(−1.04%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 67.96%27.52M sharesInsiders 0.16%65.9K sharesOther 31.88%12.91M shares
Shares outstanding 40.50M · Float 29.23M · 72.2% free float
Institutions13F, as of Mar 31, 2026
51 holders · 27.52M shares · 19 new positions · 30 increased · 14 reduced · 10 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 4.00M | 9.87% | +4.00Mnew | May 15, 2026 |
| Acorn Capital Advisors, LLC | 2.84M | 7.01% | 0 | May 15, 2026 |
| Stepstone Group LP | 2.66M | 6.57% | +2.17M | May 15, 2026 |
| Adar1 Capital Management, LLC | 2.43M | 6.01% | +1.42M | May 18, 2026 |
| Prosight Management, LP | 2.15M | 5.32% | +1.34M | May 15, 2026 |
| BVF Inc/IL | 1.98M | 4.89% | +1.98Mnew | May 15, 2026 |
| Vivo Capital, LLC | 1.93M | 4.76% | +1.93Mnew | May 20, 2026 |
| Vestal Point Capital, LP | 1.84M | 4.54% | +1.20M | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Anders Hoveincl. Acorn Capital Advisors GP 2, LLC, Acorn Bioventures, L.P. +2 more | 22.10% | 2.84M | 13D | May 30, 2025 ↗ |
| AI Biotechnology LLCincl. Len Blavatnik, Access Industries Management, LLC +1 more | 19.99% | 9.09M | 13D | Apr 7, 2026 ↗ |
| RA Capital Management, L.P. | 9.90% | 4.04M | 13G | Apr 7, 2026 ↗ |
| StepStone Group LP | 6.60% | 2.66M | 13G | Apr 7, 2026 ↗ |
| Shay Capital LLC | 6.30% | 810.2K | 13G | May 29, 2025 ↗ |
| ADAR1 Capital Management, LLC | 6.00% | 2.43M | 13G | May 15, 2026 ↗ |
| Trails Edge Capital Partners, LP | 6.00% | 2.41M | 13G | Apr 7, 2026 ↗ |
| Prosight Management, LP | 5.80% | 745.6K | 13G | Nov 28, 2025 ↗ |
| Cantor Fitzgerald Securities | 5.20% | 669.5K | 13G | Aug 14, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| AI Biotechnology LLC | 10 percent owner | 4.00M | 9.87% | Apr 7, 2026 |
| Acorn Bioventures, L.P. | 10 percent owner | 2.84M | 7.01% | May 19, 2025 |
| Acorn Bioventures 2, L.P. | 10 percent owner | 1.13M | 2.79% | May 27, 2025 |
| Isaac Manke | director | 20.6K | 0.05% | Jan 2, 2026 |
| Jason A. Leverone | officer: Chief Financial Officer | 18.8K | 0.05% | Jun 24, 2026 |
| Edward T. Mathers | director | 15.3K | 0.04% | Jan 2, 2026 |
| Nicholas A. Saccomano | director, officer: President and CEO | 11.2K | 0.03% | Jun 24, 2026 |
5 ten-percent owners hold 9.86M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 1 person has not refiled in the last 18 months (874 shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 22, 2026 | Jason A. Leveroneofficer: Chief Financial Officer | Sale | 303 | $4.40 | 18,802 |
| Jun 22, 2026 | Nicholas A. Saccomanodirector, officer: President and CEO | Sale | 86 | $4.40 | 11,247 |
| Mar 23, 2026 | Jason A. Leveroneofficer: Chief Financial Officer | Sale | 301 | $4.16 | 16,000 |
| Mar 23, 2026 | Nicholas A. Saccomanodirector, officer: President and CEO | Sale | 86 | $4.16 | 7,333 |
| Dec 22, 2025 | Jason A. Leveroneofficer: Chief Financial Officer | Sale | 302 | $2.97 | 16,301 |
| Dec 22, 2025 | Nicholas A. Saccomanodirector, officer: President and CEO | Sale | 87 | $2.97 | 7,419 |
| Sep 22, 2025 | Jason A. Leveroneofficer: Chief Financial Officer | Sale | 303 | $2.62 | 12,603 |
| Sep 22, 2025 | Nicholas A. Saccomanodirector, officer: President and CEO | Sale | 88 | $2.62 | 3,506 |
CongressHouse and Senate disclosures
Not reported.